LKLingxiang Kong

Lingxiang Kong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lingxiang Kong has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Guo Wei

    Department of General Surgery, Public health clinical center of chengdu, Chengdu, China

    2 shared publications
  • Jian Yang

    Department of Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China

    2 shared publications
  • Jiayin Yang

    Department of Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China

    2 shared publications
  • Jingsheng Yuan

    Department of Liver transplantation Laboratory, West China Hospital of Sichuan University, Chengdu, China

    2 shared publications
  • Shifeng Feng

    Department of General Surgery, Public health clinical center of chengdu, Chengdu, China

    2 shared publications
  • Tao Lv

    Department of Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China

    2 shared publications

Latest Publications

  • Open Access

    Influence of portal hypertension-associated upper gastrointestinal bleeding and acute kidney injury on liver transplantation prognosis

    by Shifeng Feng, Ou Huiying, Guo Wei, Jingsheng Yuan, Tao Lv, Jian Yang, Yong Zhao, Lingxiang Kong, Jiayin Yang

    Given that prioritization for liver transplantation (LT) is based primarily on the model for end-stage liver disease (MELD) scores, patients with lower MELD scores, who experience chronic anemia and recurrent hypotension due to gastrointestinal bleeding (GIB), tend to be marginalized. A total of 581 patients with no evidence of acute kidney injury (AKI) or chronic kidney disease 2 months before LT constituted a retrospective cohort. Within this cohort, a nested case–control study was conducted that included 134 patients with preoperative GIB (GIB(+)) and 246 matched patients without preoperative GIB (GIB(−)). A subgroup analysis was conducted based on the occurrence of AKI (AKI(− /+)) within 2 months prior to LT. The incidence of preoperative AKI was significantly higher in patients with GIB(+) compared with patients with GIB(−) (14.9% vs 8.1%, P=0.039), along with higher rates of postoperative complications and prolonged hospital stay; however, long-term survival rates were similar between the two groups. Subgroup analysis also revealed that the postoperative incidence of AKI and mortality rates at 60 days were elevated in patients with preoperative GIB(+) AKI(+) compared with patients with GIB(+) AKI(−). Furthermore, 5-year survival rates were significantly lower for patients with GIB(+) AKI(+) (65.0% vs 82.5%, P = 0.040). However, no significant difference was observed between the two subgroups of AKI(+) (GIB(+) versus GIB(−)) and the two subgroups of AKI(−) in relation to postoperative complications, short-term mortality, and long-term survival rates. Patients who experience preoperative GIB face an elevated risk of developing AKI, which is significantly correlated with a poorer prognosis for LT. A more proactive approach is needed to assess the transplant priority of patients with GIB on the waiting list.

  • Open Access

    Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study

    by Guo Wei, Yong Zhao, Shifeng Feng, Jingsheng Yuan, Gang Xu, Tao Lv, Jian Yang, Lingxiang Kong, Jiayin Yang

    Background: Portal hypertension (PHT) has been proven to be closely related to the development of hepatocellular carcinoma (HCC). Whether PHT before liver transplantation (LT) will affect the recurrence of HCC is not clear. Methods: 110 patients with depressurization of the portal vein (DPV) operations (Transjugular Intrahepatic Portosystemic Shunt—TIPS, surgical portosystemic shunt or/and splenectomy) before LT from a HCC LT cohort, matched with 330 preoperative non-DPV patients; this constituted a nested case-control study. Subgroup analysis was based on the order of DPV before or after the occurrence of HCC. Results: The incidence of acute kidney injury and intra-abdominal bleeding after LT in the DPV group was significantly higher than that in non-DPV group. The 5-year survival rates in the DPV and non-DPV group were 83.4% and 82.7% respectively (P = 0.930). In subgroup analysis, patients in the DPV prior to HCC subgroup may have a lower recurrence rate (4.7% vs.16.8%, P = 0.045) and a higher tumor free survival rate (88.9% vs.74.4%, P = 0.044) after LT under the up-to-date TNMI–II stage, while in TNM III stage, there was no difference for DPV prior to HCC subgroup compared with the DPV after HCC subgroup or the non-DPV group. Conclusion: Compared with DPV after HCC, DPV treatment before HCC can reduce the recurrence rate of HCC after early transplantation (TNM I-II). DPV before LT can reduce the recurrence of early HCC.


  • Open Access

    Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma

    by Chenhao Jiang, Zijian Liu, Jingsheng Yuan, Zhenru Wu, Lingxiang Kong, Jiayin Yang, Tao Lv

    Hepatocellular carcinoma (HCC) remains a global health challenge with a low early diagnosis rate and high mortality. The Rab GTPase (RAB) family plays an essential role in the occurrence and progression of HCC. Nonetheless, a comprehensive and systematic investigation of the RAB family has yet to be performed in HCC. We comprehensively assessed the expression landscape and prognostic significance of the RAB family in HCC and systematically correlated these RAB family genes with tumor microenvironment (TME) characteristics. Then, three RAB subtypes with distinct TME characteristics were determined. Using a machine learning algorithm, we further established a RAB score to quantify TME features and immune responses of individual tumors. Moreover, to better evaluate patient prognosis, we established a RAB risk score as an independent prognostic factor for patients with HCC. The risk models were validated in independent HCC cohorts and distinct HCC subgroups, and their complementary advantages guided clinical practice. Furthermore, we further confirmed that the knockdown of RAB13, a pivotal gene in risk models, suppressed HCC cell proliferation and metastasis by inhibiting the PI3K/AKT signaling pathway, CDK1/CDK4 expression, and epithelial-mesenchymal transition. In addition, RAB13 inhibited the activation of JAK2/STAT3 signaling and the expression of IRF1/IRF4. More importantly, we confirmed that RAB13 knockdown enhanced GPX4-dependent ferroptosis vulnerability, highlighting RAB13 as a potential therapeutic target. Overall, this work revealed that the RAB family played an integral role in forming HCC heterogeneity and complexity. RAB family-based integrative analysis contributed to enhancing our understanding of the TME and guided more effective immunotherapy and prognostic evaluation.